Rotator Cuff Injuries - Pipeline Insight, 2025

DelveInsight's, "Rotator Cuff Injuries - Pipeline Insight, 2025" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Rotator Cuff Injuries pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Rotator Cuff Injuries: Understanding

Rotator Cuff Injuries: Overview

The shoulder joint, a ball and socket type, prioritizes mobility over stability, with the glenoid being a shallow rim that provides limited coverage for the humeral head, resembling a "golf ball on a tee" or "basketball on a dinner plate." The rotator cuff, consisting of four muscles-subscapularis, supraspinatus, infraspinatus, and teres minor-originates from the scapula and inserts on the humerus, stabilizing the glenohumeral joint and facilitating key movements like internal and external rotation and abduction. Rotator cuff injuries, ranging from tendinopathy to partial and complete tears, increase with age, with up to 62% of patients over 80 affected. Age is a significant factor in both the presence and type of tear, with those over 66 years having a 50% likelihood of bilateral tears. However, there is insufficient evidence on the optimal treatment for patients under 40, as their tears are more traumatic and may respond better to surgery, though the role of non-surgical management remains unclear.

Age is the most significant factor in the development of rotator cuff disease, as it is a progressive degenerative process. Smoking, family history, and poor posture are also notable risk factors. Smokers experience larger and more symptomatic degenerative tears, increasing the likelihood of surgical intervention. A genetic predisposition is evident, as rotator cuff disease in individuals under 40 correlates with family history up to third cousins. Poor posture, especially kyphotic-lordotic, flat-back, and sway-back postures, is strongly associated with a higher incidence of rotator cuff tears. Other contributing factors include trauma, hypercholesterolemia, and occupations requiring frequent overhead movements. Partial tears are at risk for progression, with tear size, location, symptoms, and age influencing this. Larger tears are more likely to deteriorate, with anterior tears showing a greater tendency toward progression. Tears in patients over 60 are more likely to progress, while younger individuals with full-thickness tears are generally better able to adapt to stress and prevent further damage.

Rotator cuff injuries typically begin with trauma, which can be classified into macro-trauma and micro-trauma. Macro-trauma, often seen in younger patients, results in acute, complete tears, while micro-trauma leads to tendon degeneration over time, contributing to degenerative tears. Acute tears are more common in younger individuals, while degenerative tears are typically seen in older patients due to the gradual wear and weakening of the tendon. However, in cases where there is significant tendon degeneration, even a relatively small amount of force can lead to a complete tear, as the weakened tendon becomes more susceptible to injury.

The treatment of rotator cuff tears depends on the patient's age, functional demands, and the acuteness or chronicity of the tear. For complete tears in patients under 40, surgical treatment is typically recommended, as these are often traumatic injuries that respond well to surgery, although evidence for younger patients is limited. The American Academy of Orthopedic Surgeons has outlined treatment options based on evidence and expert opinion, which include non-surgical management for patients with improved function and reduced pain, repair for symptomatic patients who are healthy, and debridement or partial repair for chronic, massive tears. For patients with irreparable tears leading to painful pseudoparalysis, arthroplasty may be appropriate. Non-surgical care, including physical therapy targeting core and scapular muscles, is often effective, with similar outcomes to surgery for small and medium tears, and it remains the primary treatment for most patients, even those with full-thickness tears. Subacromial corticosteroid injections are commonly used but lack strong evidence for improving long-term outcomes when used alone.

"Rotator Cuff Injuries- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rotator Cuff Injuries pipeline landscape is provided which includes the disease overview and Rotator Cuff Injuries treatment guidelines. The assessment part of the report embraces, in depth Rotator Cuff Injuries commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rotator Cuff Injuries collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Rotator Cuff Injuries R&D. The therapies under development are focused on novel approaches to treat/improve Rotator Cuff Injuries.

Rotator Cuff Injuries Emerging Drugs Chapters

This segment of the Rotator Cuff Injuries report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Rotator Cuff Injuries Emerging Drugs

• Secukinumab: Novartis Pharmaceuticals

Secukinumab (SEC) is a fully human, monoclonal antibody that binds to and neutralises IL-17A. By inhibiting IL-17A, secukinumab aims to alleviate the inflammatory response associated with rotator cuff injuries, potentially improving symptoms and enhancing recovery. In the early stages of tendinopathy, levels of a protein called IL-17A increase in the affected tissue. IL-17A has a role in the immune system in fighting off infection, but it also plays a role in inflammation that can contribute to the development of RCT. Secukinumab is an IL-17A inhibitor, which means it aims to reduce levels of IL-17A in the body. Currently, the drug is in Phase III stage of its development for the treatment of Rotator Cuff Injuries.

Rotator Cuff Injuries: Therapeutic Assessment

This segment of the report provides insights about the different Rotator Cuff Injuries drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Rotator Cuff Injuries
• There are approx. 3+ key companies which are developing the therapies for Rotator Cuff Injuries. The companies which have their Rotator Cuff Injuries drug candidates in the most advanced stage, i.e. Phase III include, Novartis Pharmaceuticals.
• Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Rotator Cuff Injuries pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Rotator Cuff Injuries: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Rotator Cuff Injuries therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rotator Cuff Injuries drugs.

Rotator Cuff Injuries Report Insights

• Rotator Cuff Injuries Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Rotator Cuff Injuries Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Rotator Cuff Injuries drugs?
• How many Rotator Cuff Injuries drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rotator Cuff Injuries?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Rotator Cuff Injuries therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Rotator Cuff Injuries and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novartis Pharmaceuticals
• Tego Science, Inc.

Key Products

• Secukinumab
• TPX-115